Bristol Myers Squibb(CELG-RI)

PRINCETON, NJPharmaceutical1 H-1B visas (FY2023)

Focus: Bristol Myers Squibb is a $45B revenue Big Pharma company headquartered in Princeton, NJ, specializing in small molecules and biologics across oncology, hematology, immunology, cardiovascular, and neuroscience. The company commands 34,300 employees and maintains a diversified pipeline with significant patent cliff exposure.

Oncology Hematology Immunology Cardiovascular

Profile data last refreshed 18h ago · AI intelligence enriched Yesterday

Funding Stage

PUBLIC

Employees

34,300

Open Jobs

612+247 this month

Hot — 991 jobs added in 30d

Net +247 (991 new, 744 removed). Aggressive expansion phase.

5 recent layoff filings (12 mo) — 1,171 affected

9/1/2026 — Princeton, NJ · 265 affected · Layoff
4/1/2026 — Lawrence Twp, NJ · 206 affected · Layoff
4/1/2026 — Lawrence Twp, NJ · 206 affected · Layoff
+2 more

Source: state DOL filings via Big Local News

Should You Work at Bristol Myers Squibb?

AI assessment

BMS offers substantial resources and therapeutic depth for career development, but significant patent cliff exposure and recent layoff pattern present material job security risk despite current hiring activity.

Why Work Here

Access to massive commercial infrastructure and $9.3B R&D budget supporting work across five major therapeutic areas with proven market success

Data completeness

7/9 — Strong

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

1 imminent

REVLIMID

Hiring

Stable

Revenue

$45.0B

FY2025

Key Products

ELIQUIS

Deep vein thrombosis (DVT), pulmonary embolism (PE), knee replacement surgery

$18.3B

Peak

Help build intelligence for Bristol Myers Squibb

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Strong hiring momentum in R&D (61 open roles) and engineering (35 roles) signals continued investment in innovation despite recent restructuring

Peak-stage blockbusters like ELIQUIS ($18.3B revenue) and emerging programs in immunology/oncology offer exposure to blockbuster-scale drug development

Watch Out For

Significant patent cliff exposure: $22.3B in revenue at risk by 2031, with REVLIMID ($3.9B) facing 2028 loss of exclusivity and ELIQUIS ($18.3B) expiring 2031, likely triggering further restructuring
Persistent layoff activity through 2026: 4,171 cumulative WARN Act filings since Feb 2024 across Princeton and Lawrence Twp facilities, including 2,200-person 2024 restructuring, signals ongoing organizational instability and job security concerns

Generated by Claude from Bristol Myers Squibb's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Franchise blockbuster generating 41% of company revenue; faces generic erosion in 5+ years requiring pipeline replenishment.

REVLIMID

Multiple myeloma (thalidomide analog)

$3.9B

LOE Approaching1.3yr

Second-largest revenue contributor ($3.9B) but earliest major patent cliff in 2028, creating near-term revenue gap risk.

POMALYST

Multiple myeloma

$1.7B

Peak5.1yr

Immunomodulatory agent in hematology-oncology; peak revenue stable through early 2030s.

OTEZLA

Psoriatic arthritis

$877M

Peak

PDE4 inhibitor in immunology; no near-term patent cliff; smaller revenue base than franchise products.

SPRYCEL

Chronic myeloid leukemia

$510M

Post-LOEPost-LOE

Tyrosine kinase inhibitor with patent expiry imminent (Sept 2026); already in post-LOE decline phase.

IDHIFA

Acute myeloid leukemia (IDH2 inhibitor)

$119M

Peak7.8yr

Targeted oncology asset with extended patent protection through 2034; modest revenue contributor.

CAMZYOS

Hypertrophic cardiomyopathy

$105M

Peak9.4yr

Cardiac myosin inhibitor; newest commercial asset with growth potential and patent protection through 2036.

ONUREG

Acute myeloid leukemia (maintenance)

$69M

Peak3.6yr

Nucleic acid synthesis inhibitor; small revenue base but moderate patent cliff exposure by 2030.

Pipeline & Clinical Trials

BMS-986094/INX-08189

Healthy

N/A

Clinical Trials (1)

NCT01732848A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)

N/A

The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'

HIV Positive

N/A

Didanosine

HIV Infections

N/A

Clinical Trials (5)

NCT00002429Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

Phase 3

NCT00197613The Adult Antiretroviral Treatment and Resistance Study (Tshepo)

Phase 3

A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

HIV Infections

N/A

Clinical Trials (1)

NCT00135447A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen

N/A

Iberdomide

Various

N/A

Clinical Trials (5)

NCT04975997Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 3

NCT05896228Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

Healthy Participants

N/A

Clinical Trials (1)

NCT05539976A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

N/A

There is no intervention, but a diagnosis.

Rheumatologic Disorder

N/A

A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cance

Carcinoma, Non-Small-Cell Lung

N/A

Clinical Trials (1)

NCT05250817A Study of Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

N/A

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Anticoagulation

N/A

Antifibrotic therapy

Pulmonary Fibrosis

N/A

Clinical Trials (1)

NCT07722507Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

N/A

ABI-007

Pancreatic Cancer

N/A

Clinical Trials (5)

NCT00540514Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Phase 3

NCT00844649Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Palliative care assessment

Advanced Cancer

N/A

Clinical Trials (1)

NCT03837132Early Palliative Care on Quality of Life of Patients With Advanced Pancreas Cancer

N/A

Abraxane

Metastatic Pancreatic Cancer

N/A

Clinical Trials (1)

NCT02555813Treatment of Pancreatic Cancer With Abraxane

N/A

Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients

Medication Non-adherence

N/A

Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

VEXAS Syndrome

N/A

Clinical Trials (1)

NCT06377462Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection

N/A

The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuber

Rheumatic Disease

N/A

Clinical Trials (1)

NCT01685905The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection

N/A

Anti-IL8

Various

N/A

Clinical Trials (1)

NCT05210894Expanded Access for Anti-IL8

N/A

Immunotherapy

Cancer

N/A

Clinical Trials (5)

NCT00861614Study of Immunotherapy to Treat Advanced Prostate Cancer

Phase 3

NCT05002569A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

Phase 3

Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding

Gastrointestinal Hemorrhage

N/A

Clinical Trials (1)

NCT02514304Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding

N/A

SURGE

Gastrointestinal Cancer

N/A

Clinical Trials (5)

NCT04109066Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Phase 3

NCT01675076

Screening DIVA - Diffuse Vascular Disease

Peripheral Vascular Diseases

N/A

Ultrasound

Thrombosis

N/A

Clinical Trials (2)

NCT03411850Sjogrens Syndrome Measured by Ultrasound

Phase 2

NCT01137578Pediatric Catheter-related Thrombosis Imaging Study

N/A

A Study of Factors That Affect Long-Term Kidney Transplant Function

Kidney Transplant

N/A

Practical Geriatric Assessment

Geriatric Assessment

N/A

Clinical Trials (1)

NCT06870617Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)

N/A

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Hodgkin's Disease

N/A

Clinical Trials (1)

NCT02856646Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

N/A

ImmunOncoTool Condition

Cancer

N/A

Clinical Trials (1)

NCT04513678Development of ImmunOncoTool

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

HIV Infections

N/A

Patient Navigation Program

Caregiver

N/A

Clinical Trials (1)

NCT03867916Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients

N/A

BET Inhibitor

Various

N/A

Clinical Trials (1)

NCT05301972Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor

N/A

National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)

Renal Cancer

N/A

Assessment of Geriatric Evaluations Impact on New AML Guidance

AML, Adult

N/A

Clinical Trials (1)

NCT05909501Assessment of Geriatric Evaluations Impact on New AML Guidance

N/A

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV

HIV

N/A

Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation

Burns

N/A

Clinical Trials (1)

NCT00326729Fluid Shifts During Resuscitation: Impacts on Macrocirculation and Microcirculation

N/A

National Pregnancy Registry for Psychiatric Medications

Pregnant Women

N/A

A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial

Urinary Bladder Neoplasms

N/A

Collect retrospectively clinical data on reproductive outcomes

Embryo Disorder

N/A

Clinical Trials (1)

NCT04734769Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications

N/A

Interview

Caregiver

N/A

Clinical Trials (2)

NCT04051216The SMART CART Study: Health Information Technology

N/A

NCT07615764An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial

Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using

Elderly

N/A

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

Hematopathology Eligible or CAR-t Cell Treatment

N/A

Ex-vivo analysis

HIV

N/A

Clinical Trials (1)

NCT02628340Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients

N/A

Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Onco

Advanced Solid Tumors or Hematologic Malignancies

N/A

Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Com

Premature Endothelial Dysfunction

N/A

Clinical Trials (1)

NCT01499732Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects

N/A

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

HIV Infections

N/A

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progress

Rheumatoid Lung

N/A

Clinical Trials (1)

NCT04136223Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression

N/A

Samples collection: Plasma

CNS Metastases

N/A

Clinical Trials (1)

NCT04109131A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours

N/A

Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV

HIV Infections

N/A

Clinical Trials (1)

NCT00575939Antiretrovirals and Rate of Progression in Carotid Artery Intima-medial Thickness in HIV

N/A

National Register of Actionable Mutations

Solid Tumours in Advanced Stages

N/A

18F-BMS-986229 Injection

Esophagogastric Cancer

N/A

Clinical Trials (1)

NCT04161781A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

N/A

Recommendation for treatment with immunotherapy

Metastatic Solid Tumor

N/A

Clinical Trials (1)

NCT04447651Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

N/A

Comparative Tolerability of Protease Inhibitors

HIV

N/A

Clinical Trials (1)

NCT01450618Comparative Tolerability of Protease Inhibitors

N/A

Interview Prep Quick Facts

Portfolio: 501 approved products, 156 clinical trials

Top TAs: Oncology, Infectious Diseases, Immunology

H-1B (2023): 1 approval

Publications: 132 in PubMed

SEC Filings: 2 available

Open Roles: 612 active jobs

Portfolio Health

Pre-Launch205 (41%)

Launch1 (0%)

Growth5 (1%)

Peak22 (4%)

LOE Approaching91 (18%)

Post-LOE177

Therapeutic Area Focus

Oncology

84 marketed1864 pipeline

Infectious Diseases

51 marketed288 pipeline

Immunology

62 marketed243 pipeline

Cardiovascular

64 marketed140 pipeline

Financials (FY2025)

Revenue

$45.0B2%

R&D Spend

$9.3B(21%)2%

Net Income

$8.0B

Hiring Trend

Actively Hiring

612

Open Roles

+260

Added

-88

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (13)

2024-02

2,200 employees affected— New Brunswick, NJ

2024-04-25

2,200 employees affected— Princeton, NJ

2024-05-01

776 employees affected— Lawrenceville, NJ

2024-07-01

117 employees affected— Lawrenceville, NJ

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma.

Immuno-oncology technology

2026

PMID:42787530

BEACON: An Adaptive Bayesian Early-Phase Oncology Trial Design Integrating Dose Optimization and Proof-of-Concept Across Survival and Binary Endpoints.

INJECTION · INJECTABLE

CLINICAL PHARMACOLOGY Intramuscular Administration Amikacin is rapidly absorbed after intramuscular administration. In normal adult volunteers, average peak serum concentrations of about 12, 16, and 21 mcg/mL are obtained 1 hour after intramuscular administration of 250 mg (3.7 mg/kg), 375 mg (5 mg/kg), 500 mg (7.5 mg/kg), single doses, respectively. At 10 hours, serum levels are about 0.3 mcg/mL, 1.2 mcg/mL, and 2.1 mcg/mL, respectively. Tolerance studies in normal volunteers reveal that amikacin is well tolerated locally following repeated intramuscular dosing, and when given at maximally recommended doses, no ototoxicity or nephrotoxicity has been reported. There is no evidence of drug accumulation with repeated dosing for 10 days when administered according to recommended doses. With normal renal function, about 91.9% of an intramuscular dose is excreted unchanged in the urine in the first 8 hours, and 98.2% within 24 hours. Mean urine concentrations for 6 hours are 563 mcg/mL following a 250 mg dose, 697 mcg/mL following a 375 mg dose, and 832 mcg/mL following a 500 mg dose. Preliminary intramuscular studies in newborns of different weights (less than 1.5 kg, 1.5 to 2 kg, over 2 kg) at a dose of 7.5 mg/kg revealed that, like other aminoglycosides, serum half-life values were correlated inversely with post-natal age and renal clearances of amikacin. The volume of distribution indicates that amikacin, like other aminoglycosides, remains primarily in the extracellular fluid space of neonates. Repeated dosing every 12 hours in all the above groups did not demonstrate accumulation after 5 days. Intravenous Administration Single doses of 500 mg (7.5 mg/kg) administered to normal adults as an infusion over a period of 30 minutes produced a mean peak serum concentration of 38 mcg/mL at the end of the infusion, and levels of 24 mcg/mL, 18 mcg/mL, and 0.75 mcg/mL at 30 minutes, 1 hour, and 10 hours post-infusion, respectively. Eighty-four percent of the administered dose was excreted in the urine in 9 hours and about 94% within 24 hours.Repeat infusions of 7.5 mg/kg every 12 hours in normal adults were well tolerated and caused no drug accumulation. General Pharmacokinetic studies in normal adult subjects reveal the mean serum half-life to be slightly over 2 hours with a mean total apparent volume of distribution of 24 liters (28% of the body weight). By the ultrafiltration technique, reports of serum protein binding range from 0 to 11%. The mean serum clearance rate is about 100 mL/min and the renal clearance rate is 94 mL/min in subjects with normal renal function. Amikacin is excreted primarily by glomerular filtration. Patients with impaired renal function or diminished glomerular filtration pressure excrete the drug much more slowly (effectively prolonging the serum half-life). Therefore, renal function should be monitored carefully and dosage adjusted accordingly (see suggested dosage schedule under ) Following administration at the recommended

NCT00002420The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

Phase 2

NCT04392037Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

Phase 2

NCT01827111Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Phase 2

NCT04410445Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Phase 3

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

NCT03341936Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Phase 2

44 marketed140 pipeline

Metabolic Diseases

13 marketed127 pipeline

Hematology

35 marketed39 pipeline

Respiratory

40 marketed32 pipeline

79 employees affected— Lawrenceville, NJ

2025-02-01

223 employees affected— Lawrence Twp, NJ

2025-05-01

516 employees affected— Lawrence Twp, NJ

2025-06-01

68 employees affected— Lawrence Twp, NJ

2025-09-01

282 employees affected— Lawrence Twp, NJ

2025-11-01

110 employees affected— Lawrence Twp, NJ

2026-02-01

247 employees affected— Lawrence Twp, NJ

2026-04-01

206 employees affected— Lawrence Twp, NJ

2026-09-01

265 employees affected— Princeton, NJ

Source: state DOL filings, aggregated via Big Local News

1 active drug shortage

4,171 cumulative employees affected by WARN Act filings from Feb 2024 through Sept 2026, with heaviest activity in Lawrence Twp, NJ facilities; largest single event was 2,200-employee restructuring in April 2024 ($1.5B cost reduction initiative).

Severe and ongoing layoff risk; 13 WARN filings over 20 months signal structural cost-cutting cycles continuing through 2026 as company manages patent cliff and pipeline delays.

Pharmaceutical statistics

2026

PMID:42808147

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Bristol Myers Squibb(CELG-RI)

Should You Work at Bristol Myers Squibb?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (50)

Key Products by Revenue

Other Products (21)

Pipeline & Clinical Trials

Recent News · Bristol Myers Squibb(10)

Open Jobs (612)

Senior Director, Clinical Development - Prostate Cancer

Senior Therapeutic Area Specialist, Cardiovascular Community - Providence, RI

Clinical Theranostic Specialist

Senior Therapeutic Area Specialist, Cardiovascular Community - Boston Central

Medical Science Liaison - Rheumatology (N Florida and Alabama)

Regional Associate Director, US Field Medical Neuropsychiatry - Northeast Region

Senior Therapeutic Area Specialist, Cardiovascular Community – Morristown, NJ

Senior Therapeutic Area Specialist, Cardiovascular Community (Portland, ME)

Senior Therapeutic Area Specialist - Cardiovascular Specialty, Portland, OR

Senior Therapeutic Area Specialist, Oncology- WI

Director - US Field HEOR Scientist

Field Medical Excellence & Operations

Medical Science Liaison, Rheumatology (NJ & Eastern PA)

Sr. Therapeutic Area Specialist, Rheumatology - Orlando, FL

Associate Director - Key Account Management Neuroscience, COBENFY -NC/SC

Principal Scientist, Medical Physicist

Senior District Business Manager, Neuroscience - COBENFY - South Florida

Medical Science Liaison, Oncology – Melanoma & GI Tumors (VA, WV, KY)

Manager of Regional Operations (MRO) – Neuroscience – Cobenfy - Northeast and South

National Director, US Field Medical Cardiomyopathy

Associate Director, Biostatistics

Sr Medical Director Clinical Development - Radiopharmaceuticals HCC and GI cancers

Associate Director, Real World Data Strategy

Senior Manager, Real World Data Strategy

Director, Real World Data Strategy

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (13)

Research Publications(10)